JP2021501566A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501566A5
JP2021501566A5 JP2020518692A JP2020518692A JP2021501566A5 JP 2021501566 A5 JP2021501566 A5 JP 2021501566A5 JP 2020518692 A JP2020518692 A JP 2020518692A JP 2020518692 A JP2020518692 A JP 2020518692A JP 2021501566 A5 JP2021501566 A5 JP 2021501566A5
Authority
JP
Japan
Prior art keywords
antibody molecule
amino acid
antibody
acid sequence
transmembrane domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020518692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/053989 external-priority patent/WO2019070726A1/en
Publication of JP2021501566A publication Critical patent/JP2021501566A/ja
Publication of JP2021501566A5 publication Critical patent/JP2021501566A5/ja
Priority to JP2023186940A priority Critical patent/JP2024001294A/ja
Pending legal-status Critical Current

Links

JP2020518692A 2017-10-02 2018-10-02 Cd138に対する抗体分子およびその使用 Pending JP2021501566A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023186940A JP2024001294A (ja) 2017-10-02 2023-10-31 Cd138に対する抗体分子およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762566936P 2017-10-02 2017-10-02
US62/566,936 2017-10-02
US201862725880P 2018-08-31 2018-08-31
US62/725,880 2018-08-31
PCT/US2018/053989 WO2019070726A1 (en) 2017-10-02 2018-10-02 CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023186940A Division JP2024001294A (ja) 2017-10-02 2023-10-31 Cd138に対する抗体分子およびその使用

Publications (2)

Publication Number Publication Date
JP2021501566A JP2021501566A (ja) 2021-01-21
JP2021501566A5 true JP2021501566A5 (cg-RX-API-DMAC7.html) 2021-11-11

Family

ID=63966111

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020518692A Pending JP2021501566A (ja) 2017-10-02 2018-10-02 Cd138に対する抗体分子およびその使用
JP2023186940A Pending JP2024001294A (ja) 2017-10-02 2023-10-31 Cd138に対する抗体分子およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023186940A Pending JP2024001294A (ja) 2017-10-02 2023-10-31 Cd138に対する抗体分子およびその使用

Country Status (14)

Country Link
US (2) US11945868B2 (cg-RX-API-DMAC7.html)
EP (1) EP3692069A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021501566A (cg-RX-API-DMAC7.html)
KR (1) KR20200058540A (cg-RX-API-DMAC7.html)
CN (2) CN111183157A (cg-RX-API-DMAC7.html)
AU (1) AU2018345637A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020005419A2 (cg-RX-API-DMAC7.html)
CA (1) CA3074032A1 (cg-RX-API-DMAC7.html)
IL (2) IL320863A (cg-RX-API-DMAC7.html)
MX (1) MX2020003783A (cg-RX-API-DMAC7.html)
MY (1) MY205689A (cg-RX-API-DMAC7.html)
PH (1) PH12020550141A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202002248TA (cg-RX-API-DMAC7.html)
WO (1) WO2019070726A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110691793A (zh) * 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1(cd138)结合剂及其用
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
BR112021025421A2 (pt) * 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
WO2021092044A1 (en) * 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
WO2023275872A1 (en) * 2021-06-29 2023-01-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Diagnosis and treatment of pancreatic cancer
CN113514645A (zh) * 2021-07-13 2021-10-19 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) CD138抗体联合Mum1抗体在检测浆细胞中的应用
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
CN115120725B (zh) * 2022-05-30 2023-11-07 南方医科大学 Sdc1作为骨质破坏疾病药物治疗靶点的应用
CN115960231B (zh) * 2022-09-28 2026-05-22 合肥天港免疫药物有限公司 抗cd138的抗体及其应用
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN121021703A (zh) * 2025-08-26 2025-11-28 苏州系统医学研究所 Glyr1特异性抗体、其制备方法及在肿瘤防治中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP1356093A2 (en) 2000-06-21 2003-10-29 Hitachi Chemical Co., Ltd. Gene markers for lung cancer
AU2004224925C1 (en) 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP2551282A3 (en) * 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US20070054332A1 (en) * 2005-08-10 2007-03-08 Alan Rapraeger Syndecan 1 ectodomain inhibits cancer
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ES2475201T3 (es) 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
US9011864B2 (en) 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
US9446146B2 (en) 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
PL2242772T3 (pl) 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
CA2761120A1 (en) 2009-05-06 2010-11-11 Biotest Ag Uses of immunoconjugates targeting cd138
US9249467B2 (en) 2011-09-16 2016-02-02 Steven Goodison Bladder cancer detection composition, kit and associated methods
US10577543B2 (en) 2011-10-27 2020-03-03 Raymond Roger Wallage Efficient oil shale recovery method
US10117932B2 (en) 2011-12-08 2018-11-06 Biotest Ag Uses of immunoconjugates targeting CD138
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
GB201216002D0 (en) 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CN103103197A (zh) 2013-01-30 2013-05-15 百奇生物科技(苏州)有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
RU2611685C2 (ru) 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
CA3141914A1 (en) 2019-06-07 2020-12-10 Adimab, Llc Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use
BR112021025421A2 (pt) 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
US12590171B2 (en) 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof

Similar Documents

Publication Publication Date Title
JP7179464B2 (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
AU2010292342C1 (en) High affinity human antibodies to human protease-activated receptor-2
US11945868B2 (en) Antibody molecules to CD138 and uses thereof
JP2020115876A (ja) Pd−l1に対するヒト抗体
JP2023516936A (ja) Pvrig結合タンパク質及びその医薬用途
CN106068275A (zh) 抗pd‑1的人抗体
JP7604401B2 (ja) 抗体および使用方法
KR20230058074A (ko) Ilt2에 대한 항체 및 이의 용도
WO2020198370A2 (en) Therapeutic cd47 antibodies
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
US20250051473A1 (en) Anti-cd38 binding molecules and uses thereof
JP2026021532A (ja) Btla抗体
CA3207703A1 (en) Anti-s100a4 humanized antibodies, uses and methods
JP2024097985A (ja) 抗gitr抗体およびその使用
AU2018361819A1 (en) Antibodies and methods of use
EP3898694A1 (en) Antagonist antibodies against human immune checkpoint ceacam1 (cd66a) and formulations, kits, and methods of use thereof
KR20230087552A (ko) Cd45를 다량체화하는 결합 분자
CN114641500A (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
CN118679185A (zh) 抗cd38结合分子及其用途
HK40114352A (en) Antibody against btla and uses thereof
CA3250219A1 (en) ANTIBODIES AGAINST BTLA AND THEIR USES
HK40074321A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
EA050239B1 (ru) Мультиспецифические антитела, связывающиеся с bcma
EA048356B1 (ru) МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28